Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)

This article was originally published in PharmAsia News

Executive Summary

Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.


Related Content

Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value
Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)
Are Emerging Markets Part Of Big Pharma's Core Business?
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang on Lilly's FIPNET Strategies In China: An Interview With PharmAsia News


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts